Lymphoma & Plasma Cell Disorders
News
Phase 1 NHL, ALL trials placed on clinical hold
Update: On October 12, 2018, Affimed N.V. received a notification from the U.S. Food and Drug Administration (FDA) saying the agency concurred...
News
Variant not associated with CLL, AIHA, or ITP in certain patients
DUBROVNIK, CROATIA—New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or...
News
System may better predict thrombosis in lymphoma
DUBROVNIK, CROATIA—An updated scoring system can more accurately identify lymphoma patients who may require thromboprophylaxis, according to...
News
Weighing the costs of CAR T-cell therapy
The cost-effectiveness of tisagenlecleucel (Kymriah) depends on long-term clinical outcomes, which are presently unknown, according to...
News
CAR T therapy being explored in Hodgkin lymphoma
New York—Although the data set is small and not yet mature, chimeric antigen receptor (CAR) T-cell therapy appears to be a promising approach for...
Conference Coverage
Some mutation testing can be useful at CLL diagnosis
CHICAGO –
From the Journals
Frontline rituximab shows long-term success in indolent lymphoma
A study with 10-year follow-up data suggests that chemotherapy can be delayed in symptomatic indolent lymphoma patients.
News
Duvelisib bests ofatumumab as monotherapy for treatment of CLL/SLL
Final analysis of the phase 3 DUO trial has shown monotherapy with oral duvelisib results in a statistically significant improvement in...
News
5-year remission rates with combo prove durable in MCL
Long-term results of a phase 2 clinical trial of the lenalidomide and rituximab combination as first-line therapy for mantle cell lymphoma (MCL)...
Conference Coverage
Will quad therapy become the new standard in myeloma?
NEW YORK – Phase 2 studies have shown high response rates for four-drug combinations targeting multiple myeloma.
Conference Coverage
B-cell maturation antigen targeted in myeloma trials
NEW YORK – So far,